Biomarkers and Imaging of Breast Cancer.

OBJECTIVE The goals of this review are to provide background information on the definitions and applications of the general term "biomarker" and to highlight the specific roles of breast imaging biomarkers in research and clinical breast cancer care. A search was conducted of the main electronic biomedical databases (PubMed, Cochrane, Embase, MEDLINE [Ovid], Scopus, and Web of Science). The search was focused on review literature in general radiology and biomedical sciences and on reviews and primary research articles on biomarkers in breast imaging over the 15 years ending in June 2017. The keywords included "biomarker," "trial endpoints," "breast imaging," "breast cancer," "radiomics," and "precision medicine" in the titles and abstracts of the papers. CONCLUSION Clinical breast care and breast cancer-related research rely on imaging biomarkers for decision support. In the era of precision medicine and big data, the practice of radiology is likely to change. A closer integration of breast imaging with related biomedical fields and the creation of large integrated and shareable databases of clinical, molecular, and imaging biomarkers should allow the field to continue guiding breast cancer care and research.

[1]  Matthew Ingham,et al.  Cell-Cycle Therapeutics Come of Age. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Madabhushi,et al.  Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI , 2017, Breast Cancer Research.

[3]  Lihua Li,et al.  Radiomic analysis reveals DCE-MRI features for prediction of molecular subtypes of breast cancer , 2017, PloS one.

[4]  Stuart A. Taylor,et al.  Imaging biomarker roadmap for cancer studies , 2016, Nature Reviews Clinical Oncology.

[5]  A. Verbeek,et al.  Breast cancer screening effect across breast density strata: A case–control study , 2017, International journal of cancer.

[6]  A. Bardia,et al.  Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. , 2016, JAMA oncology.

[7]  S. Kurozumi,et al.  Clinical Significance of 18F-FDG-PET in Invasive Lobular Carcinoma. , 2016, Anticancer research.

[8]  Hee Jung Shin,et al.  Tumor apparent diffusion coefficient as an imaging biomarker to predict tumor aggressiveness in patients with estrogen‐receptor‐positive breast cancer , 2016, NMR in biomedicine.

[9]  T. Fujii,et al.  Clinicopathological Features of Cases with Primary Breast Cancer not Identified by 18F-FDG-PET. , 2016, Anticancer research.

[10]  Lars J. Grimm,et al.  Breast MRI radiogenomics: Current status and research implications , 2016, Journal of magnetic resonance imaging : JMRI.

[11]  Erich P Huang,et al.  Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set , 2016, npj Breast Cancer.

[12]  Erich P Huang,et al.  MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays. , 2016, Radiology.

[13]  R. Mangano,et al.  Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer , 2016, British Journal of Cancer.

[14]  Anant Madabhushi,et al.  A Radio-genomics Approach for Identifying High Risk Estrogen Receptor-positive Breast Cancers on DCE-MRI: Preliminary Results in Predicting OncotypeDX Risk Scores , 2016, Scientific Reports.

[15]  W. Weber,et al.  Molecular Imaging of Biomarkers in Breast Cancer , 2016, The Journal of Nuclear Medicine.

[16]  Paul Kinahan,et al.  Radiomics: Images Are More than Pictures, They Are Data , 2015, Radiology.

[17]  I. Nabipour,et al.  Precision medicine and molecular imaging: new targeted approaches toward cancer therapeutic and diagnosis. , 2016, American journal of nuclear medicine and molecular imaging.

[18]  Hiroko Yamashita,et al.  Identifying Triple-Negative Breast Cancer Using Background Parenchymal Enhancement Heterogeneity on Dynamic Contrast-Enhanced MRI: A Pilot Radiomics Study , 2015, PloS one.

[19]  Joseph O. Deasy,et al.  Breast cancer subtype intertumor heterogeneity: MRI‐based features predict results of a genomic assay , 2015, Journal of magnetic resonance imaging : JMRI.

[20]  J. Thrall.  Moreton Lecture: Imaging in the Age of Precision Medicine. , 2015, Journal of the American College of Radiology : JACR.

[21]  Erich P Huang,et al.  Metrology Standards for Quantitative Imaging Biomarkers. , 2015, Radiology.

[22]  J. Loscalzo,et al.  Systems medicine: evolution of systems biology from bench to bedside , 2015, Wiley interdisciplinary reviews. Systems biology and medicine.

[23]  Thomas E Yankeelov,et al.  Multiparametric Magnetic Resonance Imaging for Predicting Pathological Response After the First Cycle of Neoadjuvant Chemotherapy in Breast Cancer , 2015, Investigative radiology.

[24]  Karen Drukker,et al.  Using quantitative image analysis to classify axillary lymph nodes on breast MRI: a new application for the Z 0011 Era. , 2015, European journal of radiology.

[25]  Neema Jamshidi,et al.  Breast Cancer: Radiogenomic Biomarker Reveals Associations among Dynamic Contrast-enhanced MR Imaging, Long Noncoding RNA, and Metastasis. , 2015, Radiology.

[26]  T. Helbich,et al.  Quantitative Apparent Diffusion Coefficient as a Noninvasive Imaging Biomarker for the Differentiation of Invasive Breast Cancer and Ductal Carcinoma In Situ , 2015, Investigative radiology.

[27]  P. Fumoleau,et al.  Role of positron emission tomography for the monitoring of response to therapy in breast cancer. , 2015, The oncologist.

[28]  Breast imaging reporting and data system (BI-RADS) lexicon for breast MRI: interobserver variability in the description and assignment of BI-RADS category. , 2015, European journal of radiology.

[29]  Katherine Karakasis,et al.  Outcomes and endpoints in trials of cancer treatment: the past, present, and future. , 2015, The Lancet. Oncology.

[30]  Thomas E Yankeelov,et al.  Methods and challenges in quantitative imaging biomarker development. , 2015, Academic radiology.

[31]  H. Y. Kim,et al.  Evaluation of Malignancy Risk Stratification of Microcalcifications Detected on Mammography: A Study Based on the 5th Edition of BI-RADS , 2015, Annals of Surgical Oncology.

[32]  K. Lukong,et al.  Signaling pathways in breast cancer: therapeutic targeting of the microenvironment. , 2014, Cellular signalling.

[33]  Kenneth G. A. Gilhuijs,et al.  Association between rim enhancement of breast cancer on dynamic contrast-enhanced MRI and patient outcome: impact of subtype , 2014, Breast Cancer Research and Treatment.

[34]  P. Lambin,et al.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.

[35]  Shigehiko Kanaya,et al.  Systems Biology in the Context of Big Data and Networks , 2014, BioMed research international.

[36]  R. Stockley.  Biomarkers in chronic obstructive pulmonary disease: confusing or useful? , 2014, International journal of chronic obstructive pulmonary disease.

[37]  Martin J Yaffe,et al.  Density and breast cancer risk. , 2013, Radiology.

[38]  Yun-Hsuan Lee,et al.  Total Tumor Volume Is a Better Marker of Tumor Burden in Hepatocellular Carcinoma Defined by the Milan Criteria , 2013, World Journal of Surgery.

[39]  T. Fleming,et al.  Biomarkers and surrogate endpoints in clinical trials , 2012, Statistics in medicine.

[40]  Andre Dekker,et al.  Radiomics: the process and the challenges. , 2012, Magnetic resonance imaging.

[41]  Wendy B DeMartini,et al.  BREAST IMAGING : Positive Predictive Value of BI-RADS MR Imaging , 2012 .

[42]  Jae-Hun Kim,et al.  Imaging-Based Tumor Treatment Response Evaluation: Review of Conventional, New, and Emerging Concepts , 2012, Korean journal of radiology.

[43]  J. Aronson.  Research priorities in biomarkers and surrogate end-points. , 2012, British journal of clinical pharmacology.

[44]  Giuseppe Curigliano,et al.  New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance. , 2012, Cancer treatment reviews.

[45]  Eun-Kyung Kim,et al.  Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes , 2012, European Radiology.

[46]  Patrick Granton,et al.  Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.

[47]  Scoring System Based on BI-RADS Lexicon to Predict Probability of Malignancy in Suspicious Microcalcifications , 2012, Annals of Surgical Oncology.

[48]  H. Hricak.  Oncologic imaging: a guiding hand of personalized cancer care. , 2011, Radiology.

[49]  K. Strimbu,et al.  What are biomarkers? , 2010, Current opinion in HIV and AIDS.

[50]  Christine M. Micheel,et al.  Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease , 2010 .

[51]  Anwar R. Padhani,et al.  Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy , 2010, Targeted Oncology.

[52]  M. J. van de Vijver,et al.  A simple system for grading the response of breast cancer to neoadjuvant chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  E. Burnside,et al.  The ACR BI-RADS experience: learning from history. , 2009, Journal of the American College of Radiology : JACR.

[54]  R. Simon.  Advances in clinical trial designs for predictive biomarker discovery and validation , 2009 .

[55]  Jeanne Kowalski,et al.  Assessment of Interobserver Reproducibility in Quantitative 18F-FDG PET and CT Measurements of Tumor Response to Therapy , 2009, Journal of Nuclear Medicine.

[56]  A. Tutt,et al.  Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  T. Uematsu,et al.  Triple-negative breast cancer: correlation between MR imaging and pathologic findings. , 2009, Radiology.

[58]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[59]  Kathryn Trinkaus,et al.  PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer , 2009, Breast Cancer Research and Treatment.

[60]  Ruth M Pfeiffer,et al.  A Model Free Approach to Combining Biomarkers , 2008, Biometrical journal. Biometrische Zeitschrift.

[61]  R. Weissleder,et al.  Imaging in the era of molecular oncology , 2008, Nature.

[62]  Woo Kyung Moon,et al.  Index terms: Breast neoplasms Breast, MR , 2006 .

[63]  Lonie R. Salkowski,et al.  Use of microcalcification descriptors in BI-RADS 4th edition to stratify risk of malignancy. , 2007, Radiology.

[64]  Andreas Makris,et al.  Inter‐ and intraobserver variability in the evaluation of dynamic breast cancer MRI , 2006, Journal of magnetic resonance imaging : JMRI.

[65]  R. Castellino,et al.  Computer aided detection (CAD): an overview , 2005, Cancer imaging : the official publication of the International Cancer Imaging Society.

[66]  J. Aronson.  Biomarkers and surrogate endpoints. , 2005, British journal of clinical pharmacology.

[67]  J. Baker,et al.  BI-RADS for sonography: positive and negative predictive values of sonographic features. , 2005, AJR. American journal of roentgenology.

[68]  C. Wood,et al.  Computer Aided Detection (CAD) for Breast MRI , 2005, Technology in cancer research & treatment.

[69]  Mark J Ratain,et al.  Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  Jennifer A Harvey,et al.  Quantitative assessment of mammographic breast density: relationship with breast cancer risk. , 2004, Radiology.

[71]  James H Thrall,et al.  Biomarkers in imaging: realizing radiology's future. , 2003, Radiology.

[72]  P. Langenberg,et al.  Breast Imaging Reporting and Data System: inter- and intraobserver variability in feature analysis and final assessment. , 2000, AJR. American journal of roentgenology.

[73]  S. Orel,et al.  BI-RADS categorization as a predictor of malignancy. , 1999, Radiology.

[74]  L. Liberman,et al.  The breast imaging reporting and data system: positive predictive value of mammographic features and final assessment categories. , 1998, AJR. American journal of roentgenology.

[75]  D. Callahan.  Managed Care and the Goals of Medicine , 1998, Journal of the American Geriatrics Society.

[76]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[77]  D. Owens,et al.  Assessment of Diagnostic Technology in Health Care , 1989 .